# Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma

> **NCT07716111** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 24 (estimated)

## Conditions studied

- Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Trastuzumab Rezatecan and Retlirafusp alfa
- **DRUG:** Trastuzumab Rezatecan and Retlirafusp alfa+Pertuzumab

## Key facts

- **NCT ID:** NCT07716111
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-16
- **Primary completion:** 2027-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07716111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07716111, "Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07716111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*